Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Schwartz

Showing results (61-70 of 89) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2006
Phase II study of sorafenib in patients with advanced hepatocellular carcinomaGhassan K Abou-Alfa, Lawrence Schwartz, Sergio Ricci, et al.
EJNMMI Research|May 19, 2015
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumorsNeeta Pandit-Taskar, Joseph A O'Donoghue, Chaitanya R Divgi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2005
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistryKi Young Chung, Jinru Shia, Nancy E Kemeny, et al.
European Radiology|June 6, 2020
Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: an international multicenter studyHiram Shaish, Andrew Aukerman, Rami Vanguri, et al.
The Journal of Investigative Dermatology|November 4, 2018
Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult PopulationZelma C Chiesa Fuxench, Julie K Block, Mark Boguniewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignanciesOwen A O'Connor, Mark L Heaney, Lawrence Schwartz, et al.
Annals of Surgical Oncology|July 4, 2012
Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignanciesConstantinos T Sofocleous, Sandeep Garg, Lydia M Petrovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning MeetingMelanie B Thomas, Deborah Jaffe, Michael M Choti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerDavid B Solit, S Percy Ivy, Catherine Kopil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenouslyWm Kevin Kelly, Victoria M Richon, Owen O'Connor, et al.
Pageof 9

Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2006
Phase II study of sorafenib in patients with advanced hepatocellular carcinomaGhassan K Abou-Alfa, Lawrence Schwartz, Sergio Ricci, et al.
EJNMMI Research|May 19, 2015
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumorsNeeta Pandit-Taskar, Joseph A O'Donoghue, Chaitanya R Divgi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2005
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistryKi Young Chung, Jinru Shia, Nancy E Kemeny, et al.
European Radiology|June 6, 2020
Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: an international multicenter studyHiram Shaish, Andrew Aukerman, Rami Vanguri, et al.
The Journal of Investigative Dermatology|November 4, 2018
Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult PopulationZelma C Chiesa Fuxench, Julie K Block, Mark Boguniewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignanciesOwen A O'Connor, Mark L Heaney, Lawrence Schwartz, et al.
Annals of Surgical Oncology|July 4, 2012
Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignanciesConstantinos T Sofocleous, Sandeep Garg, Lydia M Petrovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning MeetingMelanie B Thomas, Deborah Jaffe, Michael M Choti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerDavid B Solit, S Percy Ivy, Catherine Kopil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenouslyWm Kevin Kelly, Victoria M Richon, Owen O'Connor, et al.
Pageof 9